Skip to main content
. 2022 Nov 22;16(12):826–834. doi: 10.1111/crj.13554

FIGURE 4.

FIGURE 4

Incidence rates and overall aIRR† of PHN among patients in the COPD+/HZ+ versus COPD−/HZ+ cohorts, overall and stratified by patient age at incident HZ.‡,§ Abbreviations: aIRR, adjusted incidence rate ratio; CCI, Charlson‐Quan Comorbidity Index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; HZ, herpes zoster; P, P‐value; PHN, postherpetic neuralgia; PY, person‐years; y, years. †aIRRs were calculated using generalized linear models assuming a negative binomial distribution and log link, accounting for the propensity score of being diagnosed with COPD and relevant demographic characteristics at incident HZ (i.e., age, sex, region and insurance type) and clinical characteristics before incident HZ (i.e., CCI score; asthma; use of chemotherapy, immunosuppressants and corticosteroids [short‐term oral, long‐term oral and inhaled]). aIRRs per age group are not reported as the sample sizes were not sufficient to estimate stable aIRRs by age group. ‡For the numbers of patients in each group, please refer to Table S3. §The mean overall observation periods were 21.2 ± 17.1 months in the COPD+/HZ+ cohort and 23.9 ± 17.1 months in the COPD−/HZ + cohort, with similar periods by age group.